...

首页> 外文期刊>Journal of Clinical Oncology >Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

【24h】

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

机译：Ceritinib对先前接受化学疗法和Crizotinib治疗的ALK重排非小细胞肺癌患者的全身和颅内活性的多中心II期研究：ASCEND-2的结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第24期|共13页
作者
Crino Lucio; Ahn Myung-Ju; De Marinis Filippo; Groen Harry J. M.; Wakelee Heather; Hida Toyoaki; Mok Tony; Spigel David; Felip Enriqueta; Nishio Makoto; Scagliotti Giorgio; Branle Fabrice; Emeremni Chetachi; Quadrigli Massimiliano; Zhang Jie; Shaw Alice T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [J] . Crino Lucio, Ahn Myung-Ju, De Marinis Filippo, Journal of Clinical Oncology . 2016,第24期

机译：Ceritinib对先前接受化学疗法和Crizotinib治疗的ALK重排非小细胞肺癌患者的全身和颅内活性的多中心II期研究：ASCEND-2的结果
2. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial [J] . Shaw Alice T., Kim Tae Min, Crino Lucio, Journal of Turbulence . 2017,第7期

机译：Ceritinib与化疗，患者患者以前给予化疗和爬犁癌（Ascend-5）：A随机，受控，开放标签，第3阶段试验
3. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset [J] . Kiura Katsuyuki, Imamura Fumio, Kagamu Hiroshi, Japanese journal of clinical oncology. . 2018,第4期

机译：Ceritinib的第3期VS化疗在先前用化疗和克里齐替尼治疗的ALK重新排列的NSCLC患者（Ascend-5）：日本子集
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial [O] . Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, -1

机译：ceritinib对未接受过ALK抑制剂治疗和先前接受过ALK抑制剂治疗的ALK重排非小细胞肺癌（NSCLC）患者的颅内和全身反应：第一阶段多中心开放标签ASCEND-1的最新结果试用
7. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials [O] . E. Felip, L. Crinò, D.-W. Kim, 2016

机译：141PD：Ceritinib在患者（PTS）中的全身和颅内疗效，用克里齐替尼（CRZ）预处理，ALK重新排列（ALK +）非小细胞肺癌（NSCLC）和基线脑转移（BM）：升降升降机Ascend-2试验

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号